We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 8, 2025 – Stocks in this week’s article are Halozyme Therapeutics, Inc. (HALO - Free Report) , Leidos Holdings, Inc. (LDOS - Free Report) and TransUnion (TRU - Free Report) .
Bet on These 3 Stocks with Upgraded Broker Ratings for Robust Returns
Stock markets have been hitting fresh records lately as investors gain confidence that the Federal Reserve will resume rate cuts this month. The softening labor market and rising inflation due to tariffs indicate a deteriorating macro environment, increasing the chance of rate cuts. Against such an investing backdrop, retail investors face significant challenges in selecting the right stocks and achieving strong returns.
One way to cut short this task is to follow brokers' recommendations. In this regard, stocks like Halozyme Therapeutics, Inc., Leidos Holdings, Inc. and TransUnion are worth betting on.
As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls. Brokers have a better understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment.
When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. A few other factors should be taken into account to ensure steady returns.
3 Stocks with Upgraded Broker Ratings to Buy
San Diego, CA-based Halozyme is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. HALO also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
Halozyme's 2025 earnings are expected to jump 46.1% year over year. HALO, which currently sports a Zacks Rank #1, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.
Leidos, based IN Delaware, is a global science and technology leader that serves the defense, intelligence, civil and health markets. lDOS' core capabilities include providing solutions in the fields of cybersecurity, data analytics, enterprise IT modernization, operations and logistics, sensors, collection and phenomenology, software development and systems engineering.
Leidos' 2025 earnings are projected to grow 9.2% on a year-over-year basis. LDOS, carrying a Zacks Rank #2 at present, has witnessed a 5.6% upward revision in broker ratings over the past four weeks.
Based in Chicago, IL, TransUnion is one of the leading global providers of risk and information solutions to businesses and consumers. TRU provides consumer reports, risk scores, analytical services and decision-making capabilities to businesses.
TransUnion's 2025 earnings are expected to rise 4.1% year over year. TRU, presently carrying a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
For Immediate Release
Chicago, IL – September 8, 2025 – Stocks in this week’s article are Halozyme Therapeutics, Inc. (HALO - Free Report) , Leidos Holdings, Inc. (LDOS - Free Report) and TransUnion (TRU - Free Report) .
Bet on These 3 Stocks with Upgraded Broker Ratings for Robust Returns
Stock markets have been hitting fresh records lately as investors gain confidence that the Federal Reserve will resume rate cuts this month. The softening labor market and rising inflation due to tariffs indicate a deteriorating macro environment, increasing the chance of rate cuts. Against such an investing backdrop, retail investors face significant challenges in selecting the right stocks and achieving strong returns.
One way to cut short this task is to follow brokers' recommendations. In this regard, stocks like Halozyme Therapeutics, Inc., Leidos Holdings, Inc. and TransUnion are worth betting on.
As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls. Brokers have a better understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment.
When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. A few other factors should be taken into account to ensure steady returns.
3 Stocks with Upgraded Broker Ratings to Buy
San Diego, CA-based Halozyme is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting the tumor microenvironment. HALO also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
Halozyme's 2025 earnings are expected to jump 46.1% year over year. HALO, which currently sports a Zacks Rank #1, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.
Leidos, based IN Delaware, is a global science and technology leader that serves the defense, intelligence, civil and health markets. lDOS' core capabilities include providing solutions in the fields of cybersecurity, data analytics, enterprise IT modernization, operations and logistics, sensors, collection and phenomenology, software development and systems engineering.
Leidos' 2025 earnings are projected to grow 9.2% on a year-over-year basis. LDOS, carrying a Zacks Rank #2 at present, has witnessed a 5.6% upward revision in broker ratings over the past four weeks.
Based in Chicago, IL, TransUnion is one of the leading global providers of risk and information solutions to businesses and consumers. TRU provides consumer reports, risk scores, analytical services and decision-making capabilities to businesses.
TransUnion's 2025 earnings are expected to rise 4.1% year over year. TRU, presently carrying a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial of the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2747481/bet-on-these-3-stocks-with-upgraded-broker-ratings-for-robust-returns
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.